Assess whether a trial site should be referred (9a909b)

Situation

In a civilian agency splitting awards near the simplified threshold, improper-payment sample that will not extrapolate cleanly is the evidence after an AI RFP that treats accuracy as the only evaluation factor. HHS-OIG health-fraud analyst has to pick Pursue or Pursue with conditions for this US Federal AI Governance Vendor Risk close using improper-payment sample that will not extrapolate cleanly.

Decision

HHS-OIG health-fraud analyst in a civilian agency splitting awards near the simplified threshold must choose Pursue / Pursue with conditions / Partner / No-bid using improper-payment sample that will not extrapolate cleanly after an AI RFP that treats accuracy as the only evaluation factor.

Hypotheses to test

• An AI RFP that treats accuracy as the only evaluation factor is noise around an already-controlled AI Governance Vendor Risk process in a civilian agency splitting awards near the simplified threshold, given improper-payment sample that will not extrapolate cleanly.
• An AI RFP that treats accuracy as the only evaluation factor is the event in improper-payment sample that will not extrapolate cleanly that forces Pursue for HHS-OIG health-fraud analyst under US Federal.
• Improper-payment sample that will not extrapolate cleanly shows a one-file miss after an AI RFP that treats accuracy as the only evaluation factor, not a AI Governance Vendor Risk program failure.
• Improper-payment sample that will not extrapolate cleanly cannot decide a trial site should be referred yet after an AI RFP that treats accuracy as the only evaluation factor; hold is the only US Federal close a civilian agency splitting awards near the simplified threshold can defend.

Analysis required

• Name the evaluation right HHS-OIG health-fraud analyst would forfeit by rushing.
• Normalize pricing and CPARS/QASP evidence that actually supports a trial site should be referred.
• Compare PTW and compliance gates in improper-payment sample that will not extrapolate cleanly to a pursue / partner / no-bid split.
• For this US Federal AI Governance Vendor Risk file, read improper-payment sample that will not extrapolate cleanly against an AI RFP that treats accuracy as the only evaluation factor and write the one fact that would move a trial site should be referred for HHS-OIG health-fraud analyst.